Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

Research output: Contribution to journalArticle

Abstract

Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.

Details

Authors
  • Bengt Edvardsson
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Article number479
JournalSpringerPlus
Volume2
Issue numberSep 22
Publication statusPublished - 2013
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available